Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Journey Medical Corp (DERM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: DERM (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.75
1 Year Target Price $9.75
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 82.24% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 166.56M USD | Price to earnings Ratio - | 1Y Target Price 9.75 |
Price to earnings Ratio - | 1Y Target Price 9.75 | ||
Volume (30-day avg) 4 | Beta 0.88 | 52 Weeks Range 3.54 - 8.25 | Updated Date 07/13/2025 |
52 Weeks Range 3.54 - 8.25 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-06-25 | When After Market | Estimate -0.2375 | Actual -0.18 |
Profitability
Profit Margin -14.76% | Operating Margin (TTM) -25.3% |
Management Effectiveness
Return on Assets (TTM) -5.7% | Return on Equity (TTM) -48.14% |
Valuation
Trailing PE - | Forward PE 14.16 | Enterprise Value 170661748 | Price to Sales(TTM) 2.96 |
Enterprise Value 170661748 | Price to Sales(TTM) 2.96 | ||
Enterprise Value to Revenue 3.03 | Enterprise Value to EBITDA 17.72 | Shares Outstanding 17295800 | Shares Floating 11029848 |
Shares Outstanding 17295800 | Shares Floating 11029848 | ||
Percent Insiders 30.68 | Percent Institutions 29.59 |
Upturn AI SWOT
Journey Medical Corp
Company Overview
History and Background
Journey Medical Corp., founded in 2014, focuses on acquiring, commercializing, and marketing pharmaceutical products, primarily in the dermatology space. It aims to address unmet needs in skin health through strategic acquisitions and organic growth.
Core Business Areas
- Branded Prescription Dermatology: Focuses on marketing and selling branded prescription dermatological products for various skin conditions.
- Medical Dermatology: Focuses on marketing and selling products that are indicated for skin diseases, as well as diagnostic test solutions.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development, commercialization, and finance. The organizational structure includes departments for sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- Accutane: Accutane is used to treat severe nodular acne. Journey Medical acquired rights to Accutane. Competitors include generics from Teva and Mylan. Revenue numbers for Journey Medical specifically aren't publicly broken out.
- Qbrexza: Qbrexza is a topical anticholinergic used to treat primary axillary hyperhidrosis (excessive underarm sweating). The major competitor is Botox. Market share data specifics aren't publicly available.
Market Dynamics
Industry Overview
The dermatology market is driven by factors like aging populations, increasing awareness of skin health, and advancements in treatment options. It's a competitive landscape with both established pharmaceutical companies and emerging biotech firms.
Positioning
Journey Medical focuses on acquiring and commercializing established dermatology brands, aiming to revive and grow them through focused marketing and sales efforts. Their competitive advantage lies in targeted commercialization and lifecycle management.
Total Addressable Market (TAM)
The global dermatology market is estimated to be in the billions of dollars. Journey Medical's positioning allows it to capture a segment of this market by focusing on specific product niches.
Upturn SWOT Analysis
Strengths
- Portfolio of established brands
- Experienced management team
- Targeted commercialization strategy
- Focus on unmet needs in dermatology
Weaknesses
- Reliance on acquired products
- Limited pipeline of new products
- Debt burden from acquisitions
- Competition from larger pharmaceutical companies
Opportunities
- Acquisition of additional dermatology products
- Expansion into new geographic markets
- Development of new formulations or indications for existing products
- Partnerships with other companies
Threats
- Generic competition
- Regulatory changes
- Economic downturn
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- VRX
- GNK
- ALNY
Competitive Landscape
Journey Medical competes with both large pharmaceutical companies and smaller specialty dermatology companies. Their advantage lies in a focused commercialization strategy and lifecycle management of acquired brands. Disadvantages include limited pipeline and reliance on acquisitions.
Growth Trajectory and Initiatives
Historical Growth: Journey Medical's growth has primarily been driven by acquisitions of established dermatology brands. Organic growth has been a secondary factor.
Future Projections: Future growth projections are based on analyst estimates and company guidance. Check financial websites for consensus revenue and earnings growth forecasts.
Recent Initiatives: Recent initiatives include acquisitions of new dermatology products and efforts to expand the sales and marketing reach of existing products.
Summary
Journey Medical Corp. is a pharmaceutical company focused on dermatology, primarily through acquiring and commercializing existing products. Their strategy hinges on effective commercialization, but their growth largely depends on successful acquisitions and managing debt. Generic competition and economic factors present threats. Despite these challenges, targeted commercialization and addressing unmet dermatology needs offer growth opportunities, though profitability needs to be addressed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Journey Medical Corp SEC Filings (10-K, 10-Q)
- Financial Websites (e.g., Yahoo Finance, Google Finance)
- Analyst Reports (available through financial data providers)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. Consult with a qualified financial advisor before making any investment decisions. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Journey Medical Corp
Exchange NASDAQ | Headquaters Scottsdale, AZ, United States | ||
IPO Launch date 2021-11-12 | Founder, President, CEO & Director Mr. Claude Maraoui | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 41 | Website https://journeymedicalcorp.com |
Full time employees 41 | Website https://journeymedicalcorp.com | ||
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.